biostudies-literatureUnknown10(2)Montagne A<h4>Abstract</h4>Early detection of ultrahigh-risk diffuse large B-cell lymphoma (DLBCL) is an unmet medical need to aid patient stratification for alternative treatment approaches. Metabolomics applied to biofluids of patients with cancer has emerged as a novel omics that could provide important information to better stratify these patients. In this work, the authors performed a retrospective study by nuclear magnetic resonance (NMR)-based metabolomics using plasma samples at diagnosis from 154 randomized patients with DLBCL treated by R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) (from the phase 3 REMARC [Reduced-intensity Maintenance therapy with Rituximab After R-CHOP in elderly patients with DLBCL] trial). Remarkably, a combination of 3 circulating metBlood advances358-366https://www.ebi.ac.uk/biostudies/studies/S-EPMC12828828biostudies-literatureRisk stratification of patients with diffuse large B-cell lymphoma using plasma NMR-based metabolomics at diagnosis.PMC12828828Morschhauser FChartier LRicci RBaud VHaioun CBertho GBrisou GGhesquieres HGaulard PThieblemont CFeugier POberic LGiraud NMontagne AJardin FBennani YPapastergiou TRossi CRibrag VfalseRisk stratification of patients with diffuse large B-cell lymphoma using plasma NMR-based metabolomics at diagnosis.<h4>Abstract</h4>Early detection of ultrahigh-risk diffuse large B-cell lymphoma (DLBCL) is an unmet medical need to aid patient stratification for alternative treatment approaches. Metabolomics applied to biofluids of patients with cancer has emerged as a novel omics that could provide important information to better stratify these patients. In this work, the authors performed a retrospective study by nuclear magnetic resonance (NMR)-based metabolomics using plasma samples at diagnosis from 154 randomized patients with DLBCL treated by R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) (from the phase 3 REMARC [Reduced-intensity Maintenance therapy with Rituximab After R-CHOP in elderly patients with DLBCL] trial). Remarkably, a combination of 3 circulating met2026-01-01T00:00:00Z2026 Jan2026-06-06T22:05:26.449Z2026-06-05T03:12:22.451ZS-EPMC128288284105651510.1182/bloodadvances.2025017248